Drugs for Vernal Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 29)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Histamine |
Approved, Investigational |
Phase 4 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(3H-Imidazol-4-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
|
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Eramin
Ergamine
Ergotidine
Histamine
HSM
Imidazole-4-ethylamine
NSC-33792
Β-imidazolyl-4-ethylamine
|
|
2 |
|
Hyaluronic acid |
Approved, Vet_approved |
Phase 4 |
|
9004-61-9 |
53477741 |
Synonyms:
(2S,3S,4R,5R,6R)-3-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate
(2S,3S,4R,5R,6R)-3-[(2S,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid
(2S,3S,4R,5R,6R)-3-{[(2S,3R,4R,5S,6R)-4,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5,6-trihydroxyoxane-2-carboxylate
2-Acetamido-2-deoxy-b-D-gluco-hexopyranosyl-(1->4)-b-D-gluco-hexopyranuronate
2-Acetamido-2-deoxy-b-D-gluco-hexopyranosyl-(1->4)-b-D-gluco-hexopyranuronic acid
2-Acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-beta-D-gluco-hexopyranuronate
|
2-Acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1->4)-beta-D-gluco-hexopyranuronic acid
2-Acetamido-2-deoxy-β-D-gluco-hexopyranosyl-(1->4)-β-D-gluco-hexopyranuronate
2-Acetamido-2-deoxy-β-D-gluco-hexopyranosyl-(1->4)-β-D-gluco-hexopyranuronic acid
Hyaluronan
Hyaluronate
WURCS=2.0/2,2,1/[a2122a-1b_1-5][a2122h-1b_1-5_2*ncc/3=o]/1-2/a4-b1
|
|
3 |
|
Antirheumatic Agents |
|
Phase 4 |
|
|
|
4 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
5 |
|
Adjuvants, Immunologic |
|
Phase 4 |
|
|
|
6 |
|
Anti-Allergic Agents |
|
Phase 4 |
|
|
|
7 |
|
Viscosupplements |
|
Phase 4 |
|
|
|
8 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 4 |
|
|
|
9 |
|
Histamine phosphate |
|
Phase 4 |
|
51-74-1 |
134614 |
Synonyms:
2)
4-(2-AMINOETHYL)IMIDAZOLE BIS(DIHYDROGEN PHOSPHATE)
4-(2-AMINOETHYL)IMIDAZOLE DI-ACID PHOSPHATE
HISTAMINE ACID PHOSPHATE
|
HISTAMINE BIPHOSPHATE
HISTAMINE DIHYDROGEN PHOSPHATE
HISTAMINE DIPHOSPHATE
HISTAMINE PHOSPHATE (1
|
|
10 |
|
Ophthalmic Solutions |
|
Phase 4 |
|
|
|
11 |
|
Histamine H1 Antagonists, Non-Sedating |
|
Phase 4 |
|
|
|
12 |
|
Histamine H1 Antagonists |
|
Phase 4 |
|
|
|
13 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
14 |
|
Histamine Antagonists |
|
Phase 4 |
|
|
|
15 |
|
Analgesics, Non-Narcotic |
|
Phase 4 |
|
|
|
16 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
17 |
|
Analgesics |
|
Phase 4 |
|
|
|
18 |
|
Olopatadine Hydrochloride |
|
Phase 4 |
|
140462-76-6 |
|
Synonyms:
ALO-4943A
KW-4679
OLOPATADINE HCL
PATADAY
|
|
|
19 |
|
Immunologic Factors |
|
Phase 4 |
|
|
|
20 |
|
Protective Agents |
|
Phase 4 |
|
|
|
21 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 2, Phase 3 |
|
22916-47-8 |
4189 |
Synonyms:
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
Brentan
CONOFITE
Dactarin
DERMAZOLE
DUMICOAT
Esteve brand OF miconazole
florid(nitrate)|Monistat®|R-14889
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
LORAMYC
MCZ
MICATIN
|
Miconasil nitrate
Miconazol
Miconazole
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazolum
Monistat
MONISTAT-3
MONISTAT-DERM
Nitrate, miconasil
Nitrate, miconazole
NSC-170986
Oravig
VUSION
|
|
22 |
|
Clotrimazole |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
23593-75-1 |
2812 |
Synonyms:
(Chlorotrityl)imidazole
1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole
1-(a-(2-Chlorophenyl)benzhydryl)imidazole
1-(alpha-(2-Chlorophenyl)benzhydryl)imidazole
1-(O-Chloro-a,a-diphenylbenzyl)imidazole
1-(O-Chloro-alpha,alpha-diphenylbenzyl)imidazole
1-(O-Chlorotrityl)imidazole
1-(O-Chloro-α,α-diphenylbenzyl)imidazole
1-(Α-(2-chlorophenyl)benzhydryl)imidazole
ABTRIM
ACTAVALL
Bay b 5097
BAY-5097
Bayer brand 1 OF clotrimazole
Bayer brand 2 OF clotrimazole
CANDIDEN
Canesten
Canesten 1-day cream combi-pak
Canesten 1-day therapy
Canesten 3-day therapy
Canesten 6-day therapy
CANESTEN AF
Canesten combi-pak 1-day therapy
Canesten combi-pak 3-day therapy
Canesten cream
CANESTEN CRM COMBI
CANESTEN INTERNAL
Canesten solution
CANESTEN VC
Canesten®|Lotrimin®
Canestine
Chlotrimazole
Clotrimaderm
Clotrimaderm cream
Clotrimazol
CLOTRIMAZOLE
Clotrimazole schering brand
Clotrimazolum
Desamix F
Empecid
FB b 5097
Fem care
FemCare
FUNGEDERM
GNF-PF-3499
Gyne lotrimin
Gyne-lotrimin
Gyne-lotrimin 3
Gyne-lotrimin 3 combination pack
Gyne-lotrimin combination pack
Gyne-lotrimin3
Gyne-lotrimin3 combination pack
|
Gynix
Kanesten
Klotrimazole
Lopac-C-6019
Lotrimax
Lotrimin
LOTRIMIN (TN)
Lotrimin af
Lotrimin af cream
Lotrimin af jock-itch cream
Lotrimin af lotion
Lotrimin af solution
Lotrimin cream
Lotrimin lotion
Lotrimin solution
Lotrisone
MASNODERM
mono-Baycuten
Monobaycuten
Mycelax
Mycelex
MYCELEX (TN)
Mycelex 7
Mycelex cream
Mycelex g
Mycelex otc
Mycelex solution
Mycelex troches
Mycelex twin pack
Mycelex: mycosporinrimazole
Mycelex-7
Mycelex-7 combination pack
Mycelex-g
MYCIL GOLD
Myclo cream
Myclo solution
Myclo spray solution
Myclo-gyne
Mycosporin
Mykosporin
Neo-zol cream
NSC-257473
Otomax
Pedisafe
Prestwick_120
PRIVACOM
Rimazole
Schering brand OF clotrimazole
Tibatin
Trimysten
Trivagizole 3
Veltrim
|
|
23 |
|
Anti-Infective Agents |
|
Phase 2, Phase 3 |
|
|
|
24 |
|
Calcineurin Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
25 |
|
Cyclosporins |
|
Phase 2, Phase 3 |
|
|
|
26 |
|
Antifungal Agents |
|
Phase 2, Phase 3 |
|
|
|
27 |
|
Immunosuppressive Agents |
|
Phase 2, Phase 3 |
|
|
|
28 |
|
Dermatologic Agents |
|
Phase 2, Phase 3 |
|
|
|
29 |
|
Hormones |
|
|
|
|
|
Interventional clinical trials:
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Randomized Controlled Trial Comparing Olopatadine 0.1% Ophthalmic Solution With Hylo-Dual Ophthalmic Preparation in Children With Seasonal Allergic Conjunctivitis |
Recruiting |
NCT03186755 |
Phase 4 |
Hyaluronic acid 0.05% & Ectoine 2.0%;Olopatadine hydrochloride ophthalmic solution 0.1% |
2 |
Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1% Ophthalmic Cationic Emulsion) Versus Vehicle in Patients With VKC |
Completed |
NCT00328653 |
Phase 2, Phase 3 |
Cyclosporine NOVA22007 0.05%;Cyclosporine NOVA22007 0.1%;Vehicle |
3 |
HORMONAL ROLE IN VERNAL KERATOCONJUNCTIVITIS |
Completed |
NCT05038241 |
|
|
|